Skip to content

Corticobasal Degeneration (CBD)

Summary

fleuron

  • Rare neurodegenerative disorder characterised by asymmetric cortical and basal ganglia dysfunction
  • Presents with progressive asymmetric rigidity, apraxia, and cortical sensory loss
  • Imaging shows asymmetric cortical atrophy, particularly in frontoparietal regions

Pathophysiology

  • Accumulation of hyperphosphorylated tau protein in neurons and glial cells
  • Affects cortical and subcortical regions, particularly motor cortex and basal ganglia
  • Progressive neuronal loss and gliosis in affected areas
  • Associated with mutations in the MAPT gene in some cases

Demographics

  • Typically affects individuals aged 60-80 years
  • Slight female predominance (1.5-2:1)
  • Estimated prevalence of 4.9-7.3 per 100,000 individuals

Diagnosis

  • Clinical diagnosis based on characteristic symptoms and signs:
    • Asymmetric limb rigidity and akinesia
    • Limb apraxia
    • Cortical sensory loss
    • Alien limb phenomenon
  • Supportive features:
    • Myoclonus
    • Dystonia
    • Cognitive impairment
  • Definitive diagnosis requires neuropathological confirmation

Imaging

  • MRI:
    • Asymmetric cortical atrophy, predominantly in frontoparietal regions
    • Atrophy of basal ganglia, particularly putamen
    • T2/FLAIR hyperintensity in subcortical white matter
  • FDG-PET:
    • Asymmetric hypometabolism in affected cortical regions and basal ganglia
  • DaTscan (123I-FP-CIT SPECT):
    • Asymmetric reduction in striatal dopamine transporter binding

panels-1

  • 70-year-old patient with apraxia, myoclonus and alien limb phenomenon.
  • MRI showed severe parietal atrophy but no parenchymal signal abnormality.

Treatment

  • No curative treatment available
  • Symptomatic management:
    • Levodopa for parkinsonian symptoms (often with limited response)
    • Botulinum toxin injections for dystonia and muscle spasms
    • Anticholinergics for drooling
    • Physiotherapy and occupational therapy for mobility and daily living activities
  • Supportive care:
    • Speech and language therapy for communication difficulties
    • Nutritional support
    • Psychological support for patients and caregivers
  • Ongoing research into tau-targeted therapies and neuroprotective agents

Differential diagnosis

Differential Diagnosis Distinguishing Feature
Progressive Supranuclear Palsy (PSP) Prominent early vertical gaze palsy in PSP; less asymmetry compared to CBD
Parkinson's Disease Better response to levodopa; tremor more common; less cortical involvement
Alzheimer's Disease More prominent memory impairment; less motor symptoms
Frontotemporal Dementia Less motor involvement; more behavioural and language symptoms
Multiple System Atrophy More prominent autonomic dysfunction; cerebellar signs